Business Wire

Nine-Month Figures for 2017: Sartorius Continues to Grow Profitably in a Challenging Environment

Jaa

Sartorius, a leading international partner of the biopharmaceutical industry and research, recorded further growth in the first nine months of 2017 despite a partly challenging business environment.

"This year, different influences shaped the business development of our divisions," commented Group CEO Dr. Joachim Kreuzburg on the results. "While our Lab Products & Services Division has continued to grow highly dynamically through organic growth and the expansion of its portfolio in the area of bioanalytics, growth of the Bioprocess Solutions Division, compared to a very high previous-year base, was somewhat lower than expected due to a few concurrent, temporary effects. However, the basic growth drivers of the global biopharma market remain intact, so that we continue to see high growth potential for our bioprocess business and confirm our mid-term targets."

Business development of the Sartorius Group

In the first nine months of 2017, Sartorius increased its sales revenue by 8.6% in constant currencies (reported: +8.1%) to 1,043.6 million euros. The Asia|Pacific region recorded the highest gain, with sales up 24.7% to 256.5 million euros. In EMEA2, Sartorius generated revenue of 451.0 million euros, 6.3% more than in the comparable year-earlier period. Especially in the Americas, transient manufacturing and supply bottlenecks in Bioprocess Solutions, as well as substantially softer customer demand for this Division after two very strong years, temporarily dampened growth dynamics. Accordingly, Group revenue in the region rose only moderately by 1.0% to 336.1 million euros. Order intake of the Sartorius Group rose at strong double-digit rates in both divisions in the third quarter and thus was up by 11.4% after nine months (all regional and order intake figures in constant currencies).

Despite unfavorable currency effects, underlying EBITDA increased by 7.3% compared with a strong prior-year base and reached 259.0 million euros. The Group's respective margin was 24.8% relative to 25.0% in the first nine months of the previous year; if exchange rates had remained constant, the prior-year figure would have been slightly exceeded. The relevant net profit3 for the Group grew by 6.9% from 98.9 million euros to 105.7 million euros. Earnings per ordinary share totaled 1.54 euros (9M 2016: 1.44 euros) and earnings per preference share 1.55 euros (9M 2016: 1.45 euros).

The Group's key financial indicators continued to remain at robust levels even after the most recent acquisitions of Essen BioScience in March 2017 and Umetrics in April 2017. At the end of the reporting period, the company's equity ratio was 33.6% and its ratio of net debt to underlying EBITDA stood at 2.7 (Dec. 31, 2016: 42.0%% and 1.5, respectively). The capex ratio in the first nine months was 13.6%, as expected, due to the comprehensive expansion of the Group's worldwide infrastructure.

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacture of biopharmaceuticals, recorded nine-month sales growth of 4.1% in constant currencies to 752.9 million euros, relative to a very high prior-year revenue base. Development in the first nine months of 2017 was somewhat lower than expected due to some temporary effects. Demand, which was relatively soft in North America and parts of Europe after two very dynamic years in 2015 and 2016, was additionally affected in the third quarter in particular by inventory destocking by a few customers. Moreover, no deliveries were meanwhile possible from the company’s production facility in Puerto Rico due to Hurricane Maria, and ongoing bottlenecks in a partner's delivery capacity that lasted longer than expected impacted business performance in the area of cell culture media. Consolidation of the acquisitions of kSep and Umetrics contributed around one percentage point to sales growth in the first nine months of 2017. Order intake grew more strongly than sales in the reporting period, by 7.1% in constant currencies due to strong double-digit growth in the third quarter.

Underlying EBITDA of Bioprocess Solutions rose by 2.2% to 207.0 million euros; the respective margin reached 27.5% relative to 27.9% for the year-earlier period and would have reached the prior-year level if currency exchange rates would have remained constant.

The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and in public research, recorded a significant gain in revenue, up 21.8% in constant currencies (reported: +22.0%) to 290.7 million euros. Driven by strong demand in all regions and all product areas, organic growth was at a good 7%. Expansion of the division's portfolio into bioanalytics as a result of the acquisition of Essen BioScience at the end of March 2017 contributed close to 15 percentage points to growth. Order intake in the first nine months of 2017 grew by 24.9% in constant currencies.

The division's underlying EBITDA rose sharply by 34.2% to 51.9 million euros; its respective earnings margin increased, despite unfavorable currency effects, from 16.2% to 17.9%. This was due to economies of scale related to strong organic growth and to profits contributed by acquisitions.

Full-year guidance adjusted and specified; mid-term outlook confirmed

Management assumes that the previously mentioned temporary effects will influence growth of the Bioprocess Solutions Division and, along with it, that of the Sartorius Group for the full year of 2017 as well. In view of these effects, the Sartorius Group now expects that sales revenue in constant currencies will increase by approx. 9% (previous guidance: approx. 12% to 16%). Due to adverse exchange rate effects, the underlying EBITDA margin is now projected to reach approx. the prior-year level of 25.0% (previous guidance in constant currencies: slightly more than 0.5 percentage points vs. 2016).

In view of the divisions, management now expects that sales growth for Bioprocess Solutions will reach approx. 4% (previous guidance: approx. 9% to 13%) and, the underlying EBITDA margin, including adverse exchange rate effects, will be approx. at the prior-year level of 28.0% (previous guidance in constant currencies: approx. +0.5 percentage points). For Lab Products & Services, management's projections remain basically unchanged, with sales expected to grow by about 22% (previous bandwidth 20% to 24%) and the division's underlying EBITDA margin forecasted to increase by nearly two percentage points relative to 16.0% a year ago, despite unfavorable currency effects.

The capex ratio for the current year is projected to be at the upper end of the bandwidth of around 12% to 15% of sales.

Sartorius confirms its mid-term targets.

1 Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator

2 EMEA = Europe | Middle East | Africa

3 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

This earnings release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.

Current image files

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG

www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications

www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg

Sartorius products used in pharmaceutical research

www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg

Conference call

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the company's results with analysts and investors on Wednesday, October 25, 2017, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link:

http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=8481620&linkSecurityString=2746420dc

Alternatively, you can dial into the teleconference, without registering, at:

+49 (0) 69 566 03 6000

To view the presentation, log onto:

http://www.sartorius.com/com/group/investor-relations/sartorius-ag/

Upcoming financial dates

February 6, 2018 Publication of preliminary figures for 2017

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Currently more than 7,400 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.

Key Performance Indicators for the 9-Month Period of 2017

 

Sartorius Group

  Bioprocess Solutions   Lab Products & Services

€ in millions

                         
(unless

Δ in

Δ in

Δ in

otherwise

9M

9M

%

Δ in

9M 9M

%

Δ in

9M 9M

%

Δ in

specified)  

2017

 

2016

 

reported

 

% cc(1)

 

2017

      2016   reported  

% cc(1)

  2017       2016   reported  

% cc(1)

Sales Revenue and Order Intake                                                        
Sales revenue   1043.6   965.1   8.1   8.6   752.9       726.7   3.6   4.1   290.7       238.4   22.0   21.8
- EMEA2   451.0   427.1   5.6   6.3   310.3       306.9   1.1   2.1   140.7       120.2   17.1   16.9
- Americas2   336.1   331.4   1.4   1.0   263.7       279.5   -5.7   -6.0   72.5       51.9   39.6   38.2
- Asia | Pacific2   256.5   206.6   24.2   24.7   178.9       140.3   27.5   27.8   77.6       66.3   17.1   18.2
Order intake   1096.4   988.2   11.0   11.4   802.0       752.5   6.6   7.1   294.4       235.6   24.9   24.9
Earnings                                                        
EBITDA3   259.0   241.4   7.3       207.0       202.6   2.2       51.9       38.7   34.2    
EBITDA margin3 in %   24.8   25.0           27.5       27.9           17.9       16.2        
Net profit for the period4   105.7   98.9   6.9                                            
Financial Data per Share                                                        
Earnings per ordinary share4 in €   1.54   1.44   6.9                                            
Earnings per preference share4 in €   1.55   1.45   6.8                                            
1 In constant currencies abbreviated as "cc"
2 Acc. to the customer's location
3 Underlying
4 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and
corresponding tax effects

Contact information

Sartorius AG
Petra Kirchhoff
Vice President of Corporate Communications
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
or
Andreas Theisen
Director of Investor Relations
+49 (0)551.308.1668
andreas.theisen@sartorius.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Project Bronze: Sale of the Pradera European Retail Fund 2 Portfolio18.1.2018 02:38Tiedote

An affiliate of MCAP Global Finance (UK) LLP ("MCAP") has completed the acquisition of a portfolio of six shopping centres in Spain and Italy, totalling 90,000 sqm (the “Bronze Portfolio”). Terms of the transaction were not disclosed. Formerly owned by the Pradera European Retail Fund 2 (the “Fund”), managed by Pradera, the Bronze Portfolio includes Formia: Itaca Shopping Centre, a 23,000 sqm shopping centre fully let and anchored by a Panorama hypermarket, located approximately 90km northwest of Naples; and Viterbo: Tuscia Shopping Centre, a 17,000 sqm shopping centre fully let and anchored by Coop, Italy’s largest supermarket chain, located circa 80km northwest of Rome. The transaction provided an exit for the Fund’s unitholders. Pradera will continue to serve as asset manager of the Bronze Portfolio on behalf of MCAP. Accord Europe Limited served as the exclusive financial advisor to the Fund. MCAP was self-advised. ABOUT PRADERA Pradera is a market leading specialist fund and asset

CES Asia 2018 Call for Speaker Proposals Now Open18.1.2018 00:37Tiedote

The Consumer Technology Association (CTA) today announced that its Call for Speaker Proposals for CES Asia 2018 is now open. CES Asia seeks abstracts and speakers for the CES Asia conference program. Interested candidates, including subject matter experts from throughout Asia and across industries, have the opportunity to submit a conference proposal through February 14, 2018. Industry executives, futurists and visionaries in vehicle technology, financial tech, smart cities and other target technologies are encouraged to apply. Accepted proposals will be notified by April 2, 2018. Please review the full list of conference themes, submission guidelines and speaker overview before submitting. The CES Asia conference programming features over 30 conference sessions with more than 115 highly sought after industry experts from around the globe. CES Asia speakers present to an audience of high-level industry professionals, including 1,200 members of the global media. More than 40,000 people

STATS Announces Carl Mergele as Chief Executive Officer17.1.2018 20:04Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, announced the hiring of seasoned software executive, Carl Mergele as Chief Executive Officer. Mergele has extensive experience leading and growing software companies, providing world class products and excellent customer service across a number of sectors. In November 2016, Mergele was a software executive of publicly traded NYSE-company Lexmark International, Inc. which was sold to a consortium of private equity investors for $3.6 billion, following a number of software acquisitions in the preceding four years. In addition to leading software companies as CEO, including Vista-owned companies, Mergele has served as a board member to nearly two-dozen corporate entities. Mergele will oversee the company’s next phase of growth, empowering STATS’ customers—the most innovative and successful sports teams, leagues, and brands—with the best data, intelligence and technology, giving them an edge over their competition. “I am t

Intersolar and Power2Drive Europe 2018: Solar Power Generates Mobility17.1.2018 18:40Tiedote

E-mobility is much more than just the clean mobility solution of the future. When electric vehicles are fueled by solar power, it also drives the deployment of photovoltaics forward. Intersolar Europe, the world’s leading exhibition for the solar industry, and Power2Drive Europe, the new exhibition for e-mobility and charging infrastructure, held June 20–22, 2018 in Munich, Germany under the umbrella of The smarter E Europe, will thus showcase the diverse prospects created for the environment by the combination of PV and e-mobility. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180117005988/en/ Solar Power generates mobility (Photo: Solar Promotion GmbH) Electric vehicles can be driven and charging stations can be fed with electricity from PV systems, making e-mobility a driver of the PV market. Ideally, electric vehicles are charged with solar power directly from the owner’s roof. For example, a PV system with a capacity of

Ascend Performance Materials Announces Price Increase for Nylon 6,6 Polymers, Compounds and Fibers17.1.2018 18:22Tiedote

Ascend Performance Materials announced today a price increase for its nylon 6,6 polymers, compounds and fibers due to escalating raw material costs. The price increase takes effect Feb. 1, 2018, and includes the following price changes: Materials Geography Price Increase Terms Nylon 6,6 polymers, compounds and fibers North America $0.10/lb. As contracts allow Non-contract business – price determined on an order-by-order basis Nylon 6,6 polymers, compounds and fibers Europe €0.20/kg. As contracts allow Non-contract business – price determined on an order-by-order basis Nylon 6,6 polymers, compounds and fibers Asia $0.22/kg. As contracts allow Non-contract business – price determined on an order-by-order basis Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 r

Mavenir Announces Virtualized Media Breakout Controller, Bringing 5G Edge Architectures to Legacy Networks17.1.2018 17:00Tiedote

Mavenir, focused on transforming mobile network economics for Communications Service Providers, today announced its virtualized Media Breakout Controller (vMBC), a single white box routing platform that enables carriers to host virtual Routing, Firewall, and User plane data offload. Today’s networks, whether 3G, 4G or 5G, are under pressure to provide increased bandwidth in support of LTE and its frequency combinations, and reduce latency for network interaction, resulting in a continual need to increase capacity for traffic transported through the core of the network. Multi-Access Edge Computing standardization (MEC) is trying to resolve some of these issues by placing compute functionality at the edge but it is still mostly controlled from the core, based on conventional centralized architectures. The ability to scale network functionality using virtual elements and COTS HW platforms allows network functionality to be deployed at any location. Mavenir’s innovative solution offers the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme